IMPORTANCE: Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy. OBJECTIVE: To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy. DESIGN, SETTING, AND PARTICIPANTS: This population-based, multicenter cohort study included patients with advanced melanoma experiencing grade 3 and higher irAEs after treatment with first-line ipilimumab and nivolumab between 2015 and 202...
Background: Therapeutic chances for metastatic melanoma have consistently changed over the last year...
BACKGROUND: Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAE...
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therap...
Importance: Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is prim...
IMPORTANCE Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is prima...
Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related...
Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related...
Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs), which may resu...
Background The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immuno...
Background: Therapeutic chances for metastatic melanoma have consistently changed over the last year...
BACKGROUND: Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAE...
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therap...
Importance: Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is prim...
IMPORTANCE Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is prima...
Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related...
Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related...
Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs), which may resu...
Background The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immuno...
Background: Therapeutic chances for metastatic melanoma have consistently changed over the last year...
BACKGROUND: Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAE...
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therap...